CBFA2T3::GLIS2急性髓系白血病的靶向治疗探索
该研究针对预后极差的CBFA2T3::GLIS2阳性儿童急性髓系白血病,通过全基因组CRISPR-Cas9筛选发现其对JAK2存在选择性依赖,并在体外和体内验证了JAK2敲除及I型/II型JAK2抑制剂的活性。进一步揭示MAPK通路激活是JAK2抑制剂耐药机制,联合MEK抑制剂显示协同效应,为这一高危亚型提供了潜在靶向策略。
要点
- CBFA2T3::GLIS2阳性AML对JAK2存在选择性依赖,JAK2敲除可抑制增殖并诱导凋亡。
- I型JAK2抑制剂ruxolitinib和II型CHZ868在CBFA2T3::GLIS2阳性AML模型中显示选择性体外活性。
- MAPK通路激活介导JAK2抑制剂耐药,联合MEK抑制剂显示协同效应。
核心结论
- CBFA2T3::GLIS2阳性AML依赖JAK2,JAK2抑制剂联合MEK抑制剂可能克服MAPK通路介导的耐药。
研究设计与样本
- 研究采用全基因组CRISPR-Cas9筛选,结合多西环素诱导的JAK2敲除系统、CRISPR-Cas9 ruxolitinib锚定筛选及患者来源异种移植(PDX)模型。
主要发现
- 全基因组CRISPR-Cas9筛选显示CBFA2T3::GLIS2阳性AML对JAK2存在强选择性依赖。
- JAK2敲除在CBFA2T3::GLIS2细胞系中导致体外和体内增殖受损,并在体外诱导凋亡。
- I型(ruxolitinib)和II型(CHZ868)JAK2抑制剂在CBFA2T3::GLIS2阳性AML模型中显示选择性体外活性。
- ruxolitinib锚定筛选富集了靶向MAPK通路负调控因子的sgRNA,慢性ruxolitinib耐药亚系表达致病性NRAS突变。
- ruxolitinib与MEK抑制剂联合在细胞系和PDX细胞中显示协同效应,并在CBFA2T3::GLIS2 AML PDX中显示体内活性。
临床怎么用
- 对于CBFA2T3::GLIS2阳性AML,可考虑JAK2抑制作为潜在靶向策略,但需注意MAPK通路激活导致的耐药。
- 联合MEK抑制剂可能增强JAK2抑制剂疗效,尤其对存在MAPK通路激活的病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CBFA2T3::GLIS2-positive pediatric acute myeloid leukemia (AML) remains one of the worst prognostic AML subgroups. To uncover innovative targeted therapy approaches in this disease subtype we performed genome-scale CRISPR-Cas9 screening that highlighted a strong, selective dependency on JAK2 compared to other types of cancer. Using a doxycycline-inducible JAK2 knockout (KO) system, we validated JAK2 dependency in CBFA2T3::GLIS2 cell lines, observing impaired proliferation in vitro and in vivo and apoptosis induction in vitro. Both type I (ruxolitinib) and type II (CHZ868) JAK2 inhibitors showed selective in vitro activity in CBFA2T3::GLIS2-positive AML models. To identify resistance and sensitizer mechanisms to JAK2 inhibitors, we used CRISPR-Cas9 ruxolitinib anchor screening in CBFA2T3::GLIS2 AML. sgRNAs targeting negative regulators of the MAPK pathway were enriched in the ruxolitinib-treated cells. Similarly, CBFA2T3::GLIS2 AML sublines grown to resistance under chronic ruxolitinib treatment expressed pathogenic NRAS mutations. Both approaches converged on MAPK pathway activation as a resistance mechanism to ruxolitinib treatment. Combining ruxolitinib with MEK inhibitors showed a synergistic effect in cell lines and patient-derived xenograft (PDX) cells expressing the fusion and in vivo activity in a CBFA2T3::GLIS2 AML PDX, suggesting a potential approach to target this signaling circuitry in this poor outcome AML subtype.
引用
- Gonzales F, Schneider C, Alexe G, et al. Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia. Leukemia. 2026. PMID: 41507381. doi:10.1038/s41375-025-02845-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。